Lexicon Pharmaceuticals, Inc. (LXRX)
LXRX Stock Price Chart
Explore Lexicon Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze LXRX price movements and trends.
LXRX Company Profile
Discover essential business fundamentals and corporate details for Lexicon Pharmaceuticals, Inc. (LXRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Apr 2000
Employees
103.00
Website
https://www.lexpharma.comCEO
Michael S. Exton
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Financial Timeline
Browse a chronological timeline of Lexicon Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.07.
Earnings released on 6 Aug 2025
EPS came in at $0.01 surpassing the estimated -$0.08 by +112.50%, while revenue for the quarter reached $28.87M , beating expectations by +396.71%.
Earnings released on 13 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $1.26M , missing expectations by -3.42%.
Earnings released on 6 Mar 2025
EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.18%, while revenue for the quarter reached $26.55M , beating expectations by +842.63%.
Earnings released on 12 Nov 2024
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%, while revenue for the quarter reached $1.75M , missing expectations by -72.99%.
Earnings released on 1 Aug 2024
EPS came in at -$0.17 surpassing the estimated -$0.18 by +5.56%, while revenue for the quarter reached $1.65M , missing expectations by -79.82%.
Earnings released on 2 May 2024
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%, while revenue for the quarter reached $1.13M , missing expectations by -19.29%.
Earnings released on 11 Mar 2024
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.04%, while revenue for the quarter reached $702.00K , missing expectations by -43.39%.
Earnings released on 8 Nov 2023
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $162.00K , missing expectations by -96.62%.
Earnings released on 3 Aug 2023
EPS came in at -$0.22 falling short of the estimated -$0.17 by -29.41%, while revenue for the quarter reached $317.00K , missing expectations by -92.19%.
Earnings released on 2 May 2023
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $24.00K , missing expectations by -20.00%.
Earnings released on 2 Mar 2023
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $28.00K , missing expectations by -44.00%.
Earnings released on 9 Nov 2022
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%, while revenue for the quarter reached $39.00K , missing expectations by -22.00%.
Earnings released on 2 Aug 2022
EPS came in at -$0.16 falling short of the estimated -$0.15 by -6.67%, while revenue for the quarter reached $35.00K , missing expectations by -65.00%.
Earnings released on 5 May 2022
EPS came in at -$0.16 matching the estimated -$0.16, while revenue for the quarter reached $37.00K , missing expectations by -26.00%.
Earnings released on 28 Feb 2022
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $14.00K , missing expectations by -5.26%.
Earnings released on 3 Nov 2021
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $23.00K , missing expectations by -80.83%.
Earnings released on 30 Jul 2021
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $234.00K , beating expectations by +2.24K%.
Earnings released on 6 May 2021
EPS came in at -$0.15 surpassing the estimated -$0.17 by +11.76%, while revenue for the quarter reached $27.00K , missing expectations by -75.45%.
Earnings released on 10 Mar 2021
EPS came in at -$0.05 surpassing the estimated -$0.28 by +82.14%, while revenue for the quarter reached $199.00K .
Earnings released on 29 Oct 2020
EPS came in at $0.70 surpassing the estimated $0.26 by +169.23%, while revenue for the quarter reached $6.63M , missing expectations by -23.87%.
LXRX Stock Performance
Access detailed LXRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.